Recruiting Advanced Solid Tumors Studies in New Brunswick
Study of DF9001 in Patients With Advanced Solid Tumors
DF9001-001 is a study of a new molecule that targets natural killer (NK) cells and T-cell activation signals to specific receptors on cancer cells. The study will occur in two phases. The first phase ...
Assessment of Early Radiation Oncology Involvement Alongside Standard Oncologic Care in the Managemet
To determine if the experimental approach of early radiation oncology involvement alongside standard oncologic care will result in higher HRQL at 6 months compared to the control arm receiving standar...
A Phase 1/2 Study of Inlexisertib (DCC-3116) in Patients With RAS/MAPK Pathway Mutant Solid Tumors
This is a Phase 1/2, multicenter, open label, first in human (FIH) study of inlexisertib as monotherapy, and in combination with trametinib, binimetinib, or sotorasib in patients with advanced or meta...
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
This is a first-in-human (FIH), open label Phase 1/1b / Phase 2 study in patients with advanced metastatic solid tumors refractory to standard treatment. Phase 1 will identify potential optimal biolog...
Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies
GIM-122 is a first-in-class, humanized immunoglobulin G1 kappa dual functioning monoclonal antibody (DFA). This phase 1 / 2 study plans to evaluate the safety, tolerability, pharmacokinetics and clini...
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
Researchers are looking for new ways to treat children with hepatoblastoma or rhabdomyosarcoma (RMS) that has relapsed or is refractory: * Hepatoblastoma is a common liver cancer in babies and very y...
About Advanced Solid Tumors Clinical Trials in New Brunswick
Advanced solid tumors refer to cancers that have grown beyond the original site or spread to distant organs. Many clinical trials enroll patients with various types of advanced solid tumors to test novel therapies. These trials often investigate immunotherapy, targeted therapy, and combination approaches.
There are currently 6 advanced solid tumors clinical trials recruiting participants in New Brunswick, NEW%20JERSEY. These studies are seeking a combined 833 participants. Research is being sponsored by Dragonfly Therapeutics, Rutgers, The State University of New Jersey, Deciphera Pharmaceuticals, LLC and 3 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Advanced Solid Tumors Clinical Trials in New Brunswick — FAQ
Are there advanced solid tumors clinical trials in New Brunswick?
Yes, there are 6 advanced solid tumors clinical trials currently recruiting in New Brunswick, NEW%20JERSEY. Browse the studies on this page to find one that fits.
How do I join a clinical trial in New Brunswick?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the New Brunswick research site will contact you about next steps.
Are clinical trials in New Brunswick free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many New Brunswick studies also compensate for your time and travel.
What advanced solid tumors treatments are being tested?
The 6 active trials in New Brunswick are testing new therapies including novel drugs, biologics, and treatment approaches for advanced solid tumors.
Data updated March 2, 2026 from ClinicalTrials.gov